Geisinger Health System reports its precision medicine project has enrolled over 250,000 participants and produced already medically actionable results to nearly 1,500 health system members. The MyCode study is an ambitious program from a leading integrated health system. The outcomes have implications for precision medicine.
The precision medicine project involves ongoing DNA sequencing and other health data generation now also available for 145,000 of the MyCode program enrollees. The information from this program and its collaborators is stored in a system wide biobank currently in use by researchers from Geisinger and their partners to develop advanced precision treatments.
MyCode Study Results
Findings from the study include genetic predispositions to 34 health conditions such as breast cancer, hypercholesterolemia and arrhythmia not to mention genetic links to cognitive disorders that may not be medically actionable.
MyCode Investigator Comments
Christa Martin, PhD, associate chief scientific officer and a principal investigator, reported, “There are a lot of genes that have medical actionability, like finding a change in a gene that causes breast cancer and d...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).